Inhibition of GPX4 induces the death of p53-mutant triple-negative breast cancer cells
This study demonstrates that TP53-mutant TNBC cells have unique survival pathways that can be effectively targeted. Our results illustrate the intrinsic vulnerability of TP53-mutant TNBCs to ferroptosis and highlight GPX4 as a potential target for the precision treatment of TP53-mutant TNBC.
Authors
- Amanda Lanier (ORCID: https://orcid.org/0000-0003-0791-6882)
- Reid T. Powell (ORCID: https://orcid.org/0000-0002-6242-8315)
- Jamal Hill (ORCID: https://orcid.org/0000-0002-7828-9647)
- P. D. Brown
- PETER J. A. DAVIES
- Clifford Stephan (ORCID: https://orcid.org/0000-0003-0657-6484)
- William M. Tahaney (ORCID: https://orcid.org/0000-0002-7302-3161)
- Nghi Nguyen (ORCID: https://orcid.org/0000-0001-9379-5401)
- Abhijit Mazumdar
- Cassandra Moyer
- Yanxia Ma
- Jing Qian
Institutions
- The University of Texas MD Anderson Cancer Center (US)
- Baylor College of Medicine (US)
- Texas A&M University (US)
Publication Details
- Journal
- Breast Cancer Research and Treatment
- Published
- 2026-01-01
- DOI
- https://doi.org/10.1007/s10549-025-07865-6
- Primary Topic
- Ferroptosis and cancer prognosis
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Breast Cancer Research Foundation
- Cancer Prevention and Research Institute of Texas
- Susan G. Komen
- University of Texas MD Anderson Cancer Center
- National Cancer Institute